Last $73.45 USD
Change Today -0.48 / -0.65%
Volume 3.2M
ESRX On Other Exchanges
Symbol
Exchange
ESRX is not on other exchanges.
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

express scripts holding co (ESRX) Key Developments

Triad Rx Inc. Sues Express Scripts for Terminating Contract

Triad Rx Inc. accused Express Scripts of unfairly terminating their provider agreement. Triad Rx Inc. made the allegations in a breach of contract lawsuit filed in federal court in St. Louis. According to the lawsuit, Triad and Express Scripts entered into a pharmacy provider agreement this spring. Triad said it accepts payment coupons on behalf of members through Medhealth's Compound Rx Patient Care Program, but that the practice is authorized by its agreement with Express Scripts. Triad said in its lawsuit that it will lose 45% of its customers if Express Scripts is allowed to terminate their agreement. It asks the court to enjoin Express Scripts from terminating the agreement, or award Triad damages to be determined at trial.

Express Scripts Holding Company Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Year Ending December 31, 2014; Provides Earnings Guidance for the Third Quarter of 2014

Express Scripts Holding Company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $25,111.0 million against $26,381.9 million for the same period last year. Operating income was $966 million against $1,004.3 million for the same period last year. Income before income taxes was $841.6 million against $884.8 million for the same period last year. Net income from continuing operations was $522.7 million or $0.67 per diluted share against $574.4 million or $0.68 per diluted share a year ago. Net income attributable to the company was $515.2 million or $0.67 per diluted share against $543 million or $0.66 per diluted share for the same period last year. EBITDA from continuing operations, attributable to the company, as reported was $1,516.6 million against $1,606.2 million a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $1,735.2 million against $1,746.1 million a year ago. Adjusted EBITDA from continuing operations attributable to company per adjusted claim was $5.35 compared to $4.73 a year ago. Adjusted net income attributable to the company was $939.4 million or $1.23 per diluted share against $940.3 million or $1.13 per diluted share for the same period last year. The company generated $735.5 million of cash flow during the quarter. For the six months, the company reported revenues of $48,796.0 million against $52,401.8 million for the same period last year. Operating income was $1,675.2 million against $1,847.4 million for the same period last year. Income before income taxes was $1,437.4 million against $1,523.9 million for the same period last year. Net income from continuing operations was $857.2 million or $1.09 per diluted share against $954.4 million or $1.13 per diluted share a year ago. Net income attributable to the company was $843.5 million or $1.09 per diluted share against $916.0 million or $1.10 per diluted share for the same period last year. Net cash provided by operating activities was $1,189.5 million against $782.5 million for the same period last year. Purchases of property and equipment were $208.8 million against $194.9 million for the same period last year. EBITDA from continuing operations, attributable to the company, as reported was $2,772.7 million against $3,044.5 million a year ago. Adjusted EBITDA from continuing operations, attributable to the company was $3,206.2 million against $3,339 million a year ago. Adjusted EBITDA from continuing operations attributable to company per adjusted claim was $4.97 compared to $4.40 a year ago. Adjusted net income attributable to the company was $1,718.6 million or $2.21 per diluted share against $1,765.5 million or $2.12 per diluted share for the same period last year. For the year ending December 31, 2014, the company provided adjusted earnings per share attributable to the company in the range of $4.84 to $4.92 compared to previous guidance in the range of $4.82 to $4.94. Adjusted EBITDA is expected to be in the range of $6,775 million to $6,925 million compared to previous guidance of $6,775 million to $6,975 million. Adjusted EBITDA attributable to the company per adjusted claim is expected to be in the range of $5.20 to $5.30 compared to previous guidance of $5.20 to $5.30. Cash flow from operations is expected to be in the range of $4,550 million to $5,150 million compared to previous guidance of $4,700 million to $5,300 million. Cash flow from operations is expected to be in the range of $4,550 million to $5,150 million. Effective income tax rate is expected to be between 38.0% to 38.2% compared to previous guidance in the range of 38.0% to 38.5%. Depreciation is expected in the range of $400 million to $420 million compared to previous guidance in the range of $400 million to $420 million. Capital expenditure is expected in the range of $400 million to $450 million compared to previous guidance in the range of $400 million to $450 million. The company said with regards to third quarter projections, earnings per share is expected to be between $1.27 to $1.31, up 22% to 26% year-over-year, excluding UnitedHealth.

Express Scripts Unveiling $56 Million Expansion

Express Scripts Holding Co., will unveil its newest $56 million expansion of its St. Louis headquarters July 28, 2014. The company will be opening a new office building and an addition of an existing building. It received $6.8 million in tax incentives from Missouri to construct the additional building for the promise of adding jobs. If the jobs are created, Express Scripts could be eligible for $24.7 million in additional tax credits. The 220,000-square-foot building sits on Express Scripts' north St. Louis County campus, the St. Louis Business Journal previously reported. The company also added another 10,000 square feet to an existing lab.

Express Scripts Holding Company to Report Q2, 2014 Results on Jul 29, 2014

Express Scripts Holding Company announced that they will report Q2, 2014 results After-Market on Jul 29, 2014

Express Scripts Holding Company, Q2 2014 Earnings Call, Jul 30, 2014

Express Scripts Holding Company, Q2 2014 Earnings Call, Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESRX:US $73.45 USD -0.48

ESRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cardinal Health Inc $73.83 USD +0.13
McKesson Corp $195.31 USD +0.28
Kroger Co/The $51.33 USD +0.35
Walgreen Co $60.01 USD -0.51
WellPoint Inc $115.64 USD -0.87
View Industry Companies
 

Industry Analysis

ESRX

Industry Average

Valuation ESRX Industry Range
Price/Earnings 32.6x
Price/Sales 0.6x
Price/Book 2.7x
Price/Cash Flow 15.0x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXPRESS SCRIPTS HOLDING CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.